Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bicycle Therapeutics plc BCYC

Healthcare Biotechnology
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is... see more

Recent & Breaking News (NDAQ:BCYC)

Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting

Business Wire April 14, 2023

Bicycle Therapeutics Enhances Leadership Team with Key Appointments

Business Wire April 3, 2023

Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates

Business Wire March 28, 2023

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Business Wire February 28, 2023

Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Business Wire February 28, 2023

Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009

Business Wire February 14, 2023

Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Business Wire February 8, 2023

Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium

Business Wire January 11, 2023

Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Business Wire January 4, 2023

Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting

Business Wire November 10, 2022

Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update

Business Wire November 8, 2022

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Business Wire November 4, 2022

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Business Wire November 3, 2022

Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program

Business Wire October 10, 2022

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics

Business Wire September 19, 2022

Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Business Wire September 7, 2022

Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Business Wire September 6, 2022

Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Business Wire August 4, 2022

Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides

Business Wire August 2, 2022

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry

Business Wire July 12, 2022